Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BioAlliance Pharma SA    C4X

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2015 6,97 M
EBIT 2015 -16,3 M
Net income 2015 -17,4 M
Debt 2015 1,45 M
Yield 2015 -
Sales 2016 18,4 M
EBIT 2016 -11,1 M
Net income 2016 -12,4 M
Finance 2016 0,70 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 27,8x
EV / Sales 2016 10,4x
Capitalization 192 M
More Financials
Company
Onxeo SA engages in the development of drugs for the treatment of cancer.The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP.It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad.The company was... 
Sector
Pharmaceuticals
Calendar
09/16 | 05:30amEarnings Call
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
07/31 ONXEO : Reports First Half 2015 Business Update and Consolidated Accounts
07/30 ONXEO : Reports First Half 2015 Business Update and Consolidated Accounts &ndash..
07/22 ONXEO : Update on ReLive, Livatag® International Phase III Clinical Trial in HCC
07/21 ONXEO : Update on ReLive, Livatag® international phase III clinical trial in HCC..
07/18 ONXEO : Updates on Meetings with the Financial Community During the 2nd Semester
07/13 ONXEO : Updates on Meetings with the Financial Community During the 2nd Semester
07/09 ONXEO : Presents Validive at the MASCC/ISOO International Symposium
07/08 ONXEO : Meetings with the financial community during the 2nd semester of 2015 &n..
More news
Sector news : Pharmaceuticals - NEC
11:38a HOSPIRA : Pfizer wins EU approval for $15 billion Hospira buy
11:37a PFIZER : Receives Approval From European Commission For Pending Acquisition Of H..
11:26a Wall St. falls as Apple slips to six-month low
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions